Lars Brichta

3.0k total citations
24 papers, 2.0k citations indexed

About

Lars Brichta is a scholar working on Molecular Biology, Genetics and Cellular and Molecular Neuroscience. According to data from OpenAlex, Lars Brichta has authored 24 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Genetics and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Lars Brichta's work include Neurogenetic and Muscular Disorders Research (10 papers), RNA modifications and cancer (8 papers) and RNA Research and Splicing (4 papers). Lars Brichta is often cited by papers focused on Neurogenetic and Muscular Disorders Research (10 papers), RNA modifications and cancer (8 papers) and RNA Research and Splicing (4 papers). Lars Brichta collaborates with scholars based in United States, Germany and Poland. Lars Brichta's co-authors include Paul Greengard, Brunhilde Wirth, Eric Hahnen, Marc Flajolet, Markus Rießland, Berthold Schrank, Hanns Lochmüller, Irmgard Hölker, Raoul Heller and A. Baasner and has published in prestigious journals such as Journal of Biological Chemistry, Neuron and Nature Neuroscience.

In The Last Decade

Lars Brichta

24 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Brichta United States 18 1.3k 880 400 341 313 24 2.0k
Chiara Simone Italy 25 1.1k 0.8× 668 0.8× 509 1.3× 406 1.2× 227 0.7× 40 1.9k
Johannes Schwarz Germany 18 1.4k 1.0× 376 0.4× 955 2.4× 297 0.9× 136 0.4× 27 2.3k
Lyndsey Braun United States 14 1.3k 1.0× 1.0k 1.2× 440 1.1× 1.1k 3.1× 166 0.5× 20 2.7k
Thor Ostenfeld United Kingdom 15 1.3k 0.9× 336 0.4× 1.0k 2.6× 219 0.6× 119 0.4× 24 2.6k
José A. Rodríguez‐Gómez Spain 13 1.2k 0.9× 188 0.2× 804 2.0× 246 0.7× 165 0.5× 23 2.0k
Chengyong Shen United States 24 1.1k 0.8× 171 0.2× 487 1.2× 599 1.8× 82 0.3× 41 2.0k
Benoît Funalot France 26 1.1k 0.8× 380 0.4× 813 2.0× 657 1.9× 82 0.3× 87 2.3k
Smita Saxena Switzerland 22 1.5k 1.1× 774 0.9× 1.1k 2.7× 1.4k 4.1× 103 0.3× 40 3.6k
Elize D. Haasdijk Netherlands 22 910 0.7× 492 0.6× 405 1.0× 994 2.9× 68 0.2× 28 2.1k
Rocío Ruiz Spain 21 803 0.6× 296 0.3× 466 1.2× 120 0.4× 68 0.2× 51 1.5k

Countries citing papers authored by Lars Brichta

Since Specialization
Citations

This map shows the geographic impact of Lars Brichta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Brichta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Brichta more than expected).

Fields of papers citing papers by Lars Brichta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Brichta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Brichta. The network helps show where Lars Brichta may publish in the future.

Co-authorship network of co-authors of Lars Brichta

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Brichta. A scholar is included among the top collaborators of Lars Brichta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Brichta. Lars Brichta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brichta, Lars, et al.. (2024). Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndrome. Pediatric Dermatology. 41(3). 523–525. 2 indexed citations
2.
Caparroz‐Assef, Silvana Martins, et al.. (2023). Topical Tofacitinib as Effective Therapy in Patients with Plaque Psoriasis Responsive to Systemic Drugs but with Resistant Nail Psoriasis. Skin Appendage Disorders. 9(5). 380–384. 2 indexed citations
3.
Brichta, Lars, et al.. (2021). Topical sirolimus: Difference between compounded preparations and commercial oral solution. Pediatric Dermatology. 38(4). 967–969. 1 indexed citations
4.
Graves, Steven M., Zhong Xie, Kristen A. Stout, et al.. (2019). Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. Nature Neuroscience. 23(1). 15–20. 121 indexed citations
5.
Rießland, Markus, Benjamin Kolisnyk, Tae Wan Kim, et al.. (2019). Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons. Cell stem cell. 25(4). 514–530.e8. 124 indexed citations
6.
Zhou, Ming‐Ming, Jodi Gresack, Jia Cheng, et al.. (2018). CK1δ over-expressing mice display ADHD-like behaviors, frontostriatal neuronal abnormalities and altered expressions of ADHD-candidate genes. Molecular Psychiatry. 25(12). 3322–3336. 7 indexed citations
7.
Nasca, Carla, Benedetta Bigio, Danielle Zelli, et al.. (2017). Role of the Astroglial Glutamate Exchanger xCT in Ventral Hippocampus in Resilience to Stress. Neuron. 96(2). 402–413.e5. 91 indexed citations
8.
Brichta, Lars, Vernice Jackson‐Lewis, Javier Blesa, et al.. (2015). Identification of neurodegenerative factors using translatome–regulatory network analysis. Nature Neuroscience. 18(9). 1325–1333. 83 indexed citations
9.
Brichta, Lars & Paul Greengard. (2014). Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update. Frontiers in Neuroanatomy. 8. 152–152. 162 indexed citations
10.
Brichta, Lars, Paul Greengard, & Marc Flajolet. (2013). Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. Trends in Neurosciences. 36(9). 543–554. 171 indexed citations
11.
Fourcade, Stéphane, Montserrat Ruíz, Cristina Guilera, et al.. (2010). Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Human Molecular Genetics. 19(10). 2005–2014. 76 indexed citations
12.
Brichta, Lars, Lutz Garbes, Maria Jędrzejowska, et al.. (2008). Nonsense-mediated messenger RNA decay of survival motor neuron 1 causes spinal muscular atrophy. Human Genetics. 123(2). 141–153. 26 indexed citations
13.
Rießland, Markus, Lars Brichta, Eric Hahnen, & Brunhilde Wirth. (2006). The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Human Genetics. 120(1). 101–110. 104 indexed citations
14.
Fyfe, John C., Marilyn Menotti‐Raymond, Victor A. David, et al.. (2006). An ~140-kb deletion associated with feline spinal muscular atrophy implies an essentialLIX1function for motor neuron survival. Genome Research. 16(9). 1084–1090. 32 indexed citations
15.
Brichta, Lars, Irmgard Hölker, Karsten Haug, Thomas Klockgether, & Brunhilde Wirth. (2006). In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Annals of Neurology. 59(6). 970–975. 116 indexed citations
16.
Wirth, Brunhilde, Lars Brichta, & Eric Hahnen. (2006). Spinal Muscular Atrophy: From Gene to Therapy. Seminars in Pediatric Neurology. 13(2). 121–131. 104 indexed citations
17.
Hahnen, Eric, Ilker Y. Eyüpoglu, Lars Brichta, et al.. (2006). In vitro and ex vivo evaluation of second‐generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. Journal of Neurochemistry. 98(1). 193–202. 126 indexed citations
18.
Wirth, Brunhilde, Lars Brichta, Berthold Schrank, et al.. (2006). Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Human Genetics. 119(4). 422–428. 257 indexed citations
19.
Wirth, Brunhilde, Lars Brichta, & Eric Hahnen. (2006). Spinal Muscular Atrophy and Therapeutic Prospects. Progress in molecular and subcellular biology. 44. 109–132. 34 indexed citations
20.
Brichta, Lars. (2003). Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Human Molecular Genetics. 12(19). 2481–2489. 310 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chiara Simone Breakdown of academic impact, for papers by Johannes Schwarz Breakdown of academic impact, for papers by Lyndsey Braun Breakdown of academic impact, for papers by Thor Ostenfeld Breakdown of academic impact, for papers by José A. Rodríguez‐Gómez Breakdown of academic impact, for papers by Chengyong Shen Breakdown of academic impact, for papers by Benoît Funalot Breakdown of academic impact, for papers by Smita Saxena Breakdown of academic impact, for papers by Elize D. Haasdijk Breakdown of academic impact, for papers by Rocío Ruiz
Rankless by CCL
2026